Top Markets
Coin of the day
Definium Therapeutics, Inc. Definium Therapeutics, Inc.

Definium Therapeutics, Inc.

DFTX
Rangering i aksjer #3208
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Aksjekurs
$44.42
Sist synkronisert: 2026-08-25
Markedsverdi
$5.90B
Endring (1 dag)
2.66%
Endring (1 år)
344.66%
Land
US
Handel Definium Therapeutics, Inc. (DFTX)

Kategori

Utbyttehistorikk for Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics, Inc. (aksjesymbol: DFTX) har gitt totalt 0 utbyttebetalinger.
Summen av alle utbytter (justert for aksjesplitt): 0.00
Utbytteavkastning (TTM): 0
Utbyttebetalinger for Definium Therapeutics, Inc. (DFTX) fra 2026 til 2026
Årlige utbyttebetalinger
År Utbytte (justert for aksjesplitt) Endre
Ikke nok data for de angitte datoene.
Liste over alle utbyttebetalinger
År Utbytte Endre
Ikke nok data for de angitte datoene.
Utbyttebetalinger for lignende selskaper eller konkurrenter
Selskap Antall utbyttebetalinger Land
0.00%
US
0.00%
NL
0.00%
US
64.00%
AU
0.00%
CH